SPRINT Trial: Lower Blood Pressure Target May Prevent Cardiovascular Events
A systolic blood pressure target of 120 mm Hg vs 140 mm Hg may prevent cardiovascular events and reduce mortality, according to results from the SPRINT trial.
A systolic blood pressure target of 120 mm Hg vs 140 mm Hg may prevent cardiovascular events and reduce mortality, according to results from the SPRINT trial.
Using nitric oxide during and after prolonged cardiopulmonary bypass may prevent acute kidney injury.
Andexanet alfa reversed anticoagulant effects of rivaroxaban in older healthy patients without clinical toxic effects.
Despite progress in heart disease, the number of adults achieving ideal cardiovascular health, as defined by the American Heart Association’s Simple 7 health metrics, has decreased.
Liraglutide failed to improve post-hospitalization clinical stability in patients with advanced heart failure and reduced left ventricular ejection fraction.
Breast cancer patients may benefit from concomitant treatment with candesartan to prevent decline in global left ventricular function.
Algisyl may be more effective when added to standard medical therapy vs standard medical therapy alone for heart failure patients.
Results from BEAT-HF trial show mirabergron in patients with chronic heart failure failed to improve left ventricular ejection fraction.
In the RWISE study, ranolazine did not improve SAQ angina or myocardial perfusion index in patients with microvascular dysfunction.
Results from the EMPA-REG OUTCOME trial showed empagliflozin reduced heart failure hospitalizations and cardiovascular deaths in patients with type 2 diabetes.